Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Hemostasis01:24

Disorders of Hemostasis

676
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
676
X-linked Traits01:19

X-linked Traits

53.0K
In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
53.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

590
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
Introduction to Hemostasis01:05

Introduction to Hemostasis

4.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.9K
Rh Blood Group01:19

Rh Blood Group

1.3K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

4.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

FVIII exposure, bleeding outcomes, and inhibitor development in 80 PUPs and MTPs with severe hemophilia A on emicizumab prophylaxis: real world data from the PedNet Registry.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Outcomes in venous thromboembolism with retained vs removed inferior vena cava filters: an analysis from the Registro Informatizado de Enfermedad TromboEmbólica.

Research and practice in thrombosis and haemostasis·2026
Same author

Natural History of Fetal Non-Nuchal Lymphatic Malformations: A Single Center Retrospective Study.

Prenatal diagnosis·2026
Same author

Treatment preferences of people with hemophilia and caregivers: a plain language summary.

Therapeutic advances in hematology·2026
Same author

Antiphospholipid syndrome in the paediatric population: performance of ACR-EULAR classification criteria in a controlled cohort.

Lupus science & medicine·2026
Same author

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Blood advances·2026

関連する実験動画

Updated: May 24, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K

ヘモフィリア

Pratima Chowdary1, Manuel Carcao2, Gili Kenet3

  • 1Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, UK; Department of Haematology, Cancer Institute, University College London, London, UK.

Lancet (London, England)
|March 1, 2025
PubMed
まとめ

ヘモフィリア A と B は遺伝性出血障害です. 代替因子療法,非代替療法,遺伝子療法など 現代的な治療法では 患者の生活の質を大幅に改善し 合併症を減らすことができます

さらに関連する動画

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.0K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.2K

関連する実験動画

Last Updated: May 24, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.0K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.0K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.2K

科学分野:

  • 血液学
  • 遺伝学
  • 薬理学について

背景:

  • 血液の凝固因子VIII (A型血友症) とX型血友症 (B型血友症) の欠乏によって引き起こされる先天性出血障害
  • 重度の欠乏症 (< 1% の因子活性) は,幼児期に自発的な出血を引き起こし,中度/軽度の形態は,外傷や手術後の出血とともに発生する.
  • 高い疑い指数と因子活動測定による早期診断は極めて重要です.

研究 の 目的:

  • ヘモフィリアAおよびBの現在のおよび新興の管理戦略をレビューする.
  • 治療の進歩が患者の健康に与える影響を 強調するためです
  • パーソナライズされた生涯のケアの大切さを強調するためです

主な方法:

  • ヘモフィリアの管理に関する最新の文献のレビュー.
  • 異なる治療方法の分析:因子置換療法,非置換療法,遺伝子療法
  • 予防治療のモニタリング戦略の検討

主要な成果:

  • 治療の進歩は,血友病の死亡率と罹患率を大幅に改善しました.
  • 様々な治療法は,予防,オンデマンド治療,投与,副作用のプロファイルに関して異なる利点を提供します.
  • パーソナライズされた管理,多学科チーム,患者教育が 最良の結果の鍵です.

結論:

  • 総合的なケアと 進化する治療法により 血友病患者の生活の質が向上します
  • パーソナライズされた生涯管理戦略は 患者の可能性を最大化し 病気の負担を最小限に抑えるために不可欠です
  • ヘモフィリアの治療を進めるためには,継続的な研究と教育が不可欠です.